Bone Marrow is Involved in Less than 10% of Patients with Nasal-Type NK/T Cell Lymphoma at Initial Diagnosis.
10.3346/jkms.2004.19.2.229
- Author:
Chang Okh SUNG
1
;
Young Hyeh KO
Author Information
1. Department of Pathology, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea. yhko@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
Killer Cell, Natural;
Lymphoma;
Herpesvirus 4, Human;
In Situ Hybridization;
Bone Marrow
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Biopsy;
Bone Marrow/*pathology;
Epstein-Barr Virus Infections/complications/pathology;
Female;
Herpesvirus 4, Human/genetics;
Human;
Killer Cells, Natural/*pathology;
Lymphoma, T-Cell/complications/*pathology;
Male;
Middle Aged;
Nasal Cavity/*pathology/virology;
Prognosis;
RNA, Viral/analysis;
Retrospective Studies
- From:Journal of Korean Medical Science
2004;19(2):229-233
- CountryRepublic of Korea
- Language:English
-
Abstract:
To evaluate the frequency of bone marrow involvement by nasal-type NK/T cell lymphoma, we retrospectively studied biopsy specimens from 40 patients by EBV in situ hybridization (ISH). Three patients had marrow involvement at initial diagnosis (7.5%). In one patient (1/40, 2.5%), the disease in bone marrow was recognized by routine morphological assessment, while two other patients had minimal involvement of lymphoma cells which was recognized only by EBV in situ hybridization (2/40, 5%). Two patients had a disseminated disease at diagnosis and died 6 days and 214 days after diagnosis. One patient had diffuse colonic lesion and died 82 days later. In conclusion, marrow involvement in nasal NK/T cell lymphoma is infrequent at initial diagnosis, and EBV ISH is a useful technique for identifying the minor subgroup of patients which have easily overlooked neoplastic involvement.
